Detection of Myocardial Damage in Patients With Sarcoidosis

Ovid Technologies (Wolters Kluwer Health) - Tập 120 Số 20 - Trang 1969-1977 - 2009
Manesh R. Patel1, Peter J. Cawley1, John F. Heitner1, Igor Klem1, Michele Parker1, Wael Al Jaroudi1, Trip J Meine1, JG White1, Michael D. Elliott1, Han W. Kim1, Robert M. Judd1, Raymond J. Kim1
1From the Duke Cardiovascular Magnetic Resonance Center (M.R.P., P.J.C., J.F.H., I.K., M.A.P., W.A.J., J.B.W., M.D.E., H.W.K., R.M.J., R.J.K.), Department of Medicine (M.R.P., J.F.H., I.K., M.A.P., T.J.M., J.B.W., M.D.E., H.W.K., R.M.J., R.J.K.), and Department of Radiology (R.M.J., R.J.K.), Duke University Medical Center, Durham, NC.

Tóm tắt

Background— In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect minute amounts of myocardial damage. We sought to compare DE-CMR with standard clinical evaluation for the identification of cardiac involvement. Methods and Results— Eighty-one consecutive patients with biopsy-proven extracardiac sarcoidosis were prospectively recruited for a parallel and masked comparison of cardiac involvement between (1) DE-CMR and (2) standard clinical evaluation with the use of consensus criteria (modified Japanese Ministry of Health [JMH] guidelines). Standard evaluation included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization). Patients were followed for 21±8 months for major adverse events (death, defibrillator shock, or pacemaker requirement). Patients were predominantly middle-aged (46±11 years), female (62%), and black (73%) and had chronic sarcoidosis (median, 7 years) and preserved left ventricular ejection fraction (median, 56%). DE-CMR identified cardiac involvement in 21 patients (26%) and JMH criteria in 10 (12%, 8 overlapping), a >2-fold higher rate for DE-CMR ( P =0.005). All patients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography. Pathology evaluation in 15 patients (19%) identified 4 with cardiac sarcoidosis; all 4 were positive by DE-CMR, whereas 2 were JMH positive. On follow-up, 8 had adverse events, including 5 cardiac deaths. Patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage. Conclusions— In patients with sarcoidosis, DE-CMR is more than twice as sensitive for cardiac involvement as current consensus criteria. Myocardial damage detected by DE-CMR appears to be associated with future adverse events including cardiac death, but events were few, and this needs confirmation in a larger cohort.

Từ khóa


Tài liệu tham khảo

Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP; American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999; 16: 149–173.

10.1097/00005792-195202000-00001

10.1161/circ.58.6.709777

10.1111/j.1749-6632.1976.tb47058.x

Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, Maheshwari A, Noguchi TI. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994; 11: 26–31.

10.1378/chest.103.1.253

10.1016/S0002-8703(99)70115-8

Hiraga H, Yuwa K, Hiroe M. Guideline for the diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary disease [in Japanese]. Jpn Ministry Health Welfare. 1993: 23–24.

10.1016/S0735-1097(03)00714-9

10.1016/S0140-6736(03)12389-6

10.1161/circ.103.23.2780

10.1161/circ.100.19.1992

10.1016/j.jacc.2005.01.047

10.1016/j.jacc.2003.08.011

10.1081/JCMR-120022267

10.1056/NEJM200011163432003

10.1161/circulationaha.106.635409

10.1161/circulationaha.107.723262

10.1161/01.CIR.0000078641.19365.4C

10.1093/eurheartj/ehi258

10.1161/circ.56.5.912839

10.1016/0735-1097(95)00482-3

10.1681/ASN.2006060601

Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995; 119: 167–172.

10.2214/ajr.185.1.01850110

10.1016/S0735-1097(03)00190-6

10.1016/j.jacc.2006.07.049

10.1161/circulationaha.105.570648

10.1016/j.jacc.2005.06.067

10.1371/journal.pmed.1000057

10.1016/S0002-9149(01)01978-6

10.1378/chest.128.1.30

10.1148/radiology.218.1.r01ja50215

10.1378/chest.07-2784

10.1161/circulationaha.106.178233

10.1016/j.jacc.2005.11.045

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 120 Số 20

1969-1977

Thông tin tác giả